Nordic Luveris Study

Recombinant LH Supplementation to Recombinant FSH During the Final Days of Controlled Ovarian Stimulation for IVF: a Multicentre, Prospective, Randomized, Controlled Trial

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00553293

Enrollment

526

Registered

2007-11-05

Start date

2003-08-31

Completion date

2004-11-30

Last updated

2007-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, In Vitro Fertilization

Keywords

infertility, in vitro fertilization, LH supplementation, Benefits

Brief summary

To study whether addition of human LH hormone (Luveris) during the final days of stimulation with recombinant FSH (Gonal-f) for controlled ovarian stimulation will be of benefit for patients undergoing in vitro fertilisation.

Interventions

DRUGrecombinant luteinizing hormone (Luveris)

75 iu/day form cycle day 6

DRUGrecombinant follicle stimulating hormone (Gonal-f)

rFSH 150 iu/day

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

21 Years to 40 Years

Healthy volunteers

Inclusion criteria

* Age below 40 * Infertility treatable by IVF or ICSI * Regular cycles

Exclusion criteria

* NA

Design outcomes

Primary

Measure	Time frame
Ongoing pregnancy rate per started stimulation cycle	ultrasound showing ongoing pregnancy

Secondary

Measure	Time frame
Ongoing pregnancy in subgroups of patients with lo0w serum LH levels	ultrasound for ongoing pregnancy in subgroups

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026